Point72 Asset Management L.P. Sells 339,496 Shares of CureVac (NASDAQ:CVAC)

Point72 Asset Management L.P. decreased its holdings in shares of CureVac (NASDAQ:CVAC - Free Report) by 43.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 440,509 shares of the company's stock after selling 339,496 shares during the period. Point72 Asset Management L.P. owned 0.20% of CureVac worth $1,502,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in CVAC. BNP Paribas Financial Markets bought a new stake in shares of CureVac during the fourth quarter valued at approximately $585,000. Alyeska Investment Group L.P. increased its position in shares of CureVac by 25.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after acquiring an additional 100,000 shares in the last quarter. Northern Trust Corp grew its position in CureVac by 98.1% in the 4th quarter. Northern Trust Corp now owns 60,100 shares of the company's stock worth $205,000 after purchasing an additional 29,759 shares during the period. Barclays PLC bought a new stake in CureVac in the 3rd quarter worth approximately $67,000. Finally, Geode Capital Management LLC raised its stake in CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock valued at $824,000 after buying an additional 22,491 shares during the last quarter. Institutional investors own 17.26% of the company's stock.

Wall Street Analyst Weigh In

CVAC has been the topic of several research reports. JMP Securities reissued a "market outperform" rating and issued a $16.00 target price on shares of CureVac in a research report on Friday, February 14th. UBS Group dropped their price target on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th.

CureVac Stock Performance

NASDAQ:CVAC traded up $0.22 during mid-day trading on Tuesday, hitting $4.31. 258,189 shares of the company traded hands, compared to its average volume of 747,599. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock's fifty day moving average price is $3.26 and its 200-day moving average price is $3.30. The firm has a market cap of $966.45 million, a price-to-earnings ratio of 7.83 and a beta of 2.43. CureVac has a one year low of $2.37 and a one year high of $5.28.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. Research analysts anticipate that CureVac will post 0.72 earnings per share for the current fiscal year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.